Advertisement

Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits

      Abstract

      Background: Inhibition of cholesteryl ester transfer protein (CETP) is an effective way to increase HDL levels in animals and humans. The effects of a CETP inhibitor, JTT-705, on the in vivo kinetics of apolipoprotein (apo) A-I and apo A-I gene expression in the liver and intestine were investigated. Methods: Japanese White rabbits were randomly fed normal rabbit chow LRC-4 (n=10, control) or a food admixture of LRC-4 and 0.75% JTT-705 (n=10, treated) for 7 months. An in vivo kinetics study of apo A-I was performed by injecting rabbit Math Eq-apo A-I, and apo A-I mRNA levels were quantified by RT-PCR. Results: JTT-705 significantly inhibited CETP activities, increased serum levels of HDL-cholesterol (C), HDL2-C, HDL-phospholipid, and apo A-I, and decreased HDL-triglyceride levels. The synthetic rate of apo A-I was higher in the treated rabbits than in control rabbits (13.7±2.6 versus 9.5±1.3 mg/kg per day, P<0.05), while the fractional catabolic rate was similar in the two groups. JTT-705 increased apo A-I mRNA levels in the liver without affecting those in the intestine. Conclusion: Inhibition of CETP activity by JTT-705 increases HDL levels by increasing the synthesis of apo A-I, suggesting that it could be a promising therapeutic approach for atherosclerosis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Castelli W.P.
        Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study.
        Can. J. Cardiol. 1988; 4 Suppl A: 5A-I 10A
        • Bucher H.C.
        • Griffith L.E.
        • Guyatt G.H.
        Systematic review on the risk and benefit of different cholesterol-lowering interventions.
        Arterioscler Thromb Vasc Biol. 1999; 19: 187-195
        • Vega G.L.
        • Grundy S.M.
        Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia.
        Arch. Intern. Med. 1994; 154: 73-82
        • Tall A.R.
        Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies.
        J. Intern. Med. 1995; 237: 5-12
        • Saku K.
        • Zhang B.
        • Ohta T.
        • Arakawa K.
        Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis.
        J. Am. Coll. Cardiol. 1999; 33: 436-443
        • Navab M.
        • Berliner J.A.
        • Subbanagounder G.
        • Hama S.
        • Lusis A.J.
        • Castellani L.W.
        • et al.
        HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.
        Arterioscler Thromb Vasc Biol. 2001; 21: 481-488
        • Paszty C.
        • Maeda N.
        • Verstuyft J.
        • Rubin E.M.
        Apolipoprotein Al transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.
        J. Clin Invest. 1994; 94: 899-903
        • Plump A.S.
        • Scott C.J.
        • Breslow J.L.
        Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.
        Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 9607-9611
        • Rubin E.M.
        • Krauss R.M.
        • Spangler E.A.
        • Verstuyft J.G.
        • Clift S.M.
        Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al.
        Nature. 1991; 353: 265-267
        • Saku K.
        • Gartside P.S.
        • Hynd B.A.
        • Kashyap M.L.
        Mechanism of action of gemfibrozil on lipoprotein metabolism.
        J. Clin. Invest. 1985; 75: 1702-1712
        • Frick M.H.
        • Elo O.
        • Haapa K.
        • Heinonen O.P.
        • Heinsalmi P.
        • Helo P.
        • et al.
        Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
        N. Engl. J. Med. 1987; 317: 1237-1245
        • Huang Z.
        • lnazu A.
        • Nohara A.
        • Higashikata T.
        • Mabuchi H.
        Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia.
        Clin. Sci. (London). 2002; 103: 587-594
        • de Grooth G.J.
        • Kuivenhoven J.A.
        • Stalenhoef A.F.
        • de Graaf J.
        • Zwinderman A.H.
        • Posma J.L.
        • et al.
        Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
        Circulation. 2002; 105: 2159-2165
        • Okamoto H.
        • Yonemori F.
        • Wakitani K.
        • Minowa T.
        • Maeda K.
        • Shinkai H.
        A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
        Nature. 2000; 406: 203-207
        • Rubins H.B.
        • Robins S.J.
        • Collins D.
        • Fye C.L.
        • Anderson J.W.
        • Elam M.B.
        • et al.
        Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
        N Engl. J. Med. 1999; 341: 410-418
        • Tall A.R.
        An overview of reverse cholesterol transport.
        Eur. Heart J. 1998; 19 Suppl A: A31-A35
        • Marotti K.R.
        • Castle C.K.
        • Boyle T.P.
        • Lin A.H.
        • Murray R.W.
        • Melchior G.W.
        Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein.
        Nature. 1993; 364: 73-75
        • Foger B.
        • Chase M.
        • Amar M.J.
        • Vaisman B.L.
        • Shamburek R.D.
        • Paigen B.
        • et al.
        Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.
        J. Biol. Chem. 1999; 274: 36912-36920
        • Melchior G.W.
        • Castle C.K.
        • Murray R.W.
        • Blake W.L.
        • Dinh D.M.
        • Marotti K.R.
        Apolipoprotein A-I metabolism in cholesteryl ester transfer protein transgenic mice. Insights into the mechanisms responsible for low plasma high density lipoprotein levels.
        J. Biol. Chem. 1994; 269: 8044-8051
        • Hayek T.
        • Azrolan N.
        • Verdery R.B.
        • Walsh A.
        • Chajek-Shaul T.
        • Agellon L.B.
        • et al.
        Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice.
        J. Clin Invest. 1993; 92: 1143-1152
        • Rittershaus C.W.
        • Miller D.P.
        • Thomas U.
        • Picard M.D.
        • Honan C.M.
        • Emmett C.D.
        • et al.
        Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis.
        Arterioscler Thromb Vasc. Biol. 2000; 20: 2106-2112
        • Sugano M.
        • Makino N.
        • Sawada S.
        • Otsuka S.
        • Watanabe M.
        • Okamoto H.
        • et al.
        Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits.
        J. Biol. Chem. 1998; 273: 5033-5036
        • von Eckardstein A.
        • Assmann G.
        Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?.
        Curr. Opin. Lipidol. 2000; 11: 627-637
        • Kastelein J.J.
        • lsaacsohn J.L.
        • Ose L.
        • Hunninghake D.B.
        • Frohlich J.
        • Davidson M.H.
        • et al.
        Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
        Am. J. Cardiol. 2000; 86: 221-223
        • Rashid S.
        • Uffelman K.D.
        • Barrett P.H.
        • Lewis G.F.
        Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit.
        Circulation. 2002; 106: 2955-2960
        • Sawada S.
        • Sugano M.
        • Makino N.
        • Okamoto H.
        • Tsuchida K.
        Secretion of prebeta HDL increases with the suppression of cholesteryl ester transfer protein in Hep G2 cells.
        Atherosclerosis. 1999; 146: 291-298
      1. Jayo JM, Schwenke DC, Clarkson TB. Aterosclerosis research. In: Manning PJ, Ringler GH, Newcomer CE, editors. The biology of the laboratory rabbit. San Diego: Academic Press; 1994. p. 367–80.

        • Zhang B.
        • Saku K.
        • Hirata K.
        • Liu R.
        • Tateishi K.
        • Shiomi M.
        • et al.
        Quantitative characterization of insulin-glucose response in Watanabe heritable hyperlipidemic and cholesterol-fed rabbits and the effect of cilazapril.
        Metabolism. 1994; 43: 360-366
        • Zhang B.
        • Fan P.
        • Tanaka H.
        • Saku K.
        Angiotensin II type-I receptor antagonist, CS-866, reduces blood pressure without affecting glucose/insulin metabolism in cholesterol-fed rabbits.
        Br. J. Biomed. Sci. 2001; 58: 217-225
        • Zhang B.
        • Shimoji E.
        • Tanaka H.
        • Keijiro S.
        Evaluation of apolipoprotein A-I kinetics in rabbits in vivo using in situ and exogenous radioiodination methods.
        Lipids. 2003; 38: 209-218
        • Kwon M.J.
        • Song Y.S.
        • Choi M.S.
        • Park S.J.
        • Jeong K.S.
        • Song Y.O.
        Cholesteryl ester transfer protein activity and atherogenic parameters in rabbits supplemented with cholesterol and garlic powder.
        Life Sci. 2003; 72: 2953-2964
        • Okamoto H.
        • Iwamoto Y.
        • Maki M.
        • Sotani T.
        • Yonemori F.
        • Wakitani K.
        Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals.
        Eur. J. Pharmacol. 2003; 466: 147-154
        • Vega G.L.
        • Gylling H.
        • Nichols A.V.
        • Grundy S.M.
        Evaluation of a method for study of kinetics of autologous apolipoprotein A-I.
        J. Lipid Res. 1991; 32: 867-875
        • Nichols A.V.
        • Gong E.L.
        • Blanche P.J.
        • Forte T.M.
        • Anderson D.W.
        Effects of guanidine hydrochloride on human plasma high density lipoproteins.
        Biochim. Biophys. Acta. 1976; 446: 226-239
        • Laemmli U.K.
        Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
        Nature. 1970; 227: 680-685
        • Goldstein J.L.
        • Basu S.K.
        • Brown M.S.
        Receptor-mediated endocytosis of low-density lipoprotein in cultured cells.
        Methods Enzymol. 1985; 98: 241-260
        • Bilheimer D.W.
        • Eisenberg S.
        • Levy R.I.
        The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations.
        Biochim. Biophys. Acta. 1972; 260: 212-221
        • McFarlane A.S.
        Efficient trace-labelling of proteins with iodine.
        Nature. 1958; 182: 53
        • Brousseau M.E.
        • Santamarina-Fojo S.
        • Zech L.A.
        • Berard A.M.
        • Vaisman B.L.
        • Meyn S.M.
        • et al.
        Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner.
        J. Clin Invest. 1996; 97: 1844-1851
        • Saku K.
        • von Eckardstein A.
        • Zhang B.
        • Liu R.
        • Jimi S.
        • Ou J.
        • In vivo kinetics of human apolipoprotein A-I variants in rabbits
        • et al.
        Eur. J. Clin Invest. 1999; 29: 196-203
        • Saku K.
        • Liu R.
        • Ohkubo K.
        • Bai H.
        • Hirata K.
        • Yamamoto K.
        • et al.
        In vivo conversion of recombinant human proapolipoprotein Al (rh-Met-proapo Al) to apolipoprotein Al in rabbits.
        Biochim. Biophys. Acta. 1993; 1167: 257-263
        • Havel R.J.
        • Eder H.A.
        • Bragdon J.H.
        The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
        J. Clin Invest. 1955; 34: 1345-1353
        • Winer J.
        • Jung C.K.
        • Shackel I.
        • Williams P.M.
        Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro.
        Anal. Biochem. 1999; 270: 41-49
      2. SAS/STAT User’s Guide, Version 6, vol. 2. 4th ed. Cary, NC: SAS Institute Inc.; 1990. p. 891–1456.

        • Saku K.
        • Harada R.
        • Yamamoto K.
        • Ying H.
        • Ozaki I.
        • Arakawa K.
        Apolipoprotein Al mRNA levels in WHHL rabbits.
        Atherosclerosis. 1990; 84: 73-74
        • Chao Y.S.
        • Yamin T.T.
        • Thompson G.M.
        • Kroon P.A.
        Tissue-specific expression of genes encoding apolipoprotein E and apolipoprotein A-I in rabbits.
        J. Biol. Chem. 1984; 259: 5306-5309
        • Asayama K.
        • Hayashibe H.
        • Dobashi K.
        • Uchida N.
        • Nakane T.
        • Kodera K.
        • et al.
        Increased serum cholesteryl ester transfer protein in obese children.
        Obes. Res. 2002; 10: 439-446
        • Ebenbichler C.F.
        • Laimer M.
        • Kaser S.
        • Ritsch A.
        • Sandhofer A.
        • Weiss H.
        • et al.
        Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women.
        Arterioscler Thromb Vasc. Biol. 2002; 22: 1465-1469
        • Radeau T.
        • Robb M.
        • Lau P.
        • Borthwick J.
        • McPherson R.
        Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man.
        Atherosclerosis. 1998; 139: 369-376
        • Benoist F.
        • Lau P.
        • McDonnell M.
        • boelle H.
        • Milne R.
        • McPherson R.
        Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue.
        J. Biol. Chem. 1997; 272: 23572-23577
        • Radeau T.
        • Lau P.
        • Robb M.
        • McDonnell M.
        • Ailhaud G.
        • McPherson R.
        Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content.
        J. Lipid Res. 1995; 36: 2552-2561
        • Blake W.L.
        • Ulrich R.G.
        • Marotti K.R.
        • Melchior G.W.
        The development of fatty liver is accelerated in transgenic mice expressing cynomolgus monkey cholesteryl ester transfer protein.
        Biochem. Biophys. Res. Commun. 1994; 205: 1257-1263
        • Kobayashi J.
        • Okamoto H.
        • Otabe M.
        • Bujo H.
        • Saito Y.
        Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage.
        Atherosclerosis. 2002; 162: 131-135
        • Kawano K.
        • Qin S.C.
        • Lin M.
        • Tall A.R.
        • Jiang X.C.
        Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo.
        J. Biol. Chem. 2000; 275: 29477-29481
        • Jiang X.C.
        • Masucci-Magoulas L.
        • Mar J.
        • Lin M.
        • Walsh A.
        • Breslow J.L.
        • et al.
        Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles.
        J. Biol. Chem. 1993; 268: 27406-27412
        • Hayek T.
        • Chajek-Shaul T.
        • Walsh A.
        • Agellon L.B.
        • Moulin P.
        • Tall A.R.
        • et al.
        An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-25 mediated depression of high density lipoprotein cholesterol levels.
        J. Clin. Invest. 1992; 90: 505-510
        • Yamashita S.
        • Hirano K.
        • Sakai N.
        • Matsuzawa Y.
        Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein.
        Biochim. Biophys. Acta. 2000; 1529: 257-275
        • Ikewaki K.
        • Rader D.J.
        • Sakamoto T.
        • Nishiwaki M.
        • Wakimoto N.
        • Schaefer J.R.
        • et al.
        Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-Il in human cholesteryl ester transfer protein deficiency.
        J. Clin. Invest. 1993; 92: 1650-1658
        • Yamashita S.
        • Maruyama T.
        • Hirano K.
        • Sakai N.
        • Nakajima N.
        • Matsuzawa Y.
        Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia.
        Atherosclerosis. 2000; 152: 271-285
        • Malchinkhuu E.
        • Sato K.
        • Muraki T.
        • Ishikawa K.
        • Kuwabara A.
        • Okajima F.
        Assessment of the role of sphingosine 1-phosphate and its receptors in high-density lipoprotein-induced stimulation of astroglial cell function.
        Biochem. J. 2003; 370: 817-827
        • Kimura T.
        • Sato K.
        • Kuwabara A.
        • Tomura H.
        • Ishiwara M.
        • Kobayashi I.
        • et al.
        Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells.
        J. Biol. Chem. 2001; 276: 31780-31785
        • Miura S.I.
        • Fujino M.
        • Matsuo Y.
        • Kawamura A.
        • Tanigawa H.
        • Nishikawa H.
        • et al.
        High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells.
        Arterioscler Thromb Vasc. Biol. 2003; 23: 802-808
        • Plump A.S.
        • Masucci-Magoulas L.
        • Bruce C.
        • Bisgaier C.L.
        • Breslow J.L.
        • Tall A.R.
        Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.
        Arterioscler Thromb Vasc. Biol. 1999; 19: 1105-1110